
ASCO GI 2021
CONTENTS
Online First
Oesophageal and Gastric Cancer
Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels
Gut microbiome DELIVERs nivolumab forecast in gastric cancer
OS benefit for trifluridine/tipiracil in advanced gastric cancer from third-line onward
Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer
Adjuvant nivolumab: good quality-of-life
Adding docetaxel to adjuvant S-1 reduces gastric cancer relapse
Anal and Colorectal Cancer
First-line pembrolizumab shows superior PFS in MSI-H/dMMR mCRC
Short-course radiotherapy with delayed surgery better for elderly rectal cancer patients
Circulating tumour DNA predicts recurrence in colorectal cancer
Neoadjuvant pembrolizumab in locally-advanced rectal cancer: primary results

Prognostic value of tumour deposits in stage 3 colon cancer patients
Ipilimumab/nivolumab plus panitumumab in patients with microsatellite-stable mCRC
Preliminary surgery salvage data after watch & wait policy from OPERA trial
Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers
Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy

Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC
Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy
Hepatobiliary Cancer
Ivosidenib in second-line improves OS in IDH1-mutant cholangiocarcinoma
Final phase 2 results of second-line infigratinib for advanced cholangiocarcinoma
Landmark OS for HCC, updated IMbrave150 data
Second-line pembrolizumab after progression on sorafenib benefits OS/PFS in advanced HCC
Phase 2 study supports first-line pembrolizumab in advanced HCC
Yttrium-90 (Y-90) glass microspheres for HCC
Sorafenib extends PFS, but not OS, for HCC transcatheter arterial chemoembolisation
Zanidatamab provides ORR in HER2+ biliary tract cancer
Pancreatic Cancer
Borderline resectable pancreatic cancer: phase 2 results
No survival benefit for olaparib in BRCA-mutated metastatic pancreatic cancer
